Granted Patent B2

US 12,522,663 · App. 18/452,699 · Granted Jan 13, 2026

Inventors: Oliver Seifert (Stuttgart, DE); Roland Kontermann (Nürtingen, DE); Fabian Richter (Kirchheim unter Teck, DE)

Assignee: UNIVERSITAT STUTTGART

C07K16/2863A61K39/39533A61P35/00C07K16/2878C07K16/32A61K38/00C07K2317/30C07K2317/526C07K2317/60C07K2317/62C07K2317/64C07K2317/66C07K2317/73C07K2317/75C07K2317/92C07K2317/94G01N33/5091

Abstract

Claims (48)

1 . A multivalent antigen-binding protein complex specifically binding human epidermal growth factor receptor 3 (HER3) and epidermal growth factor receptor (EGFR), wherein the antigen-binding protein complex comprises a dual binding module (DBM1) comprising:

(a) antigen binding sites selected from the group consisting of:

(i) amino acid positions 1 to 119 and 125 to 232 of SEQ ID NO: 19; and

(ii) amino acid positions 1 to 123 and 129 to 235 of SEQ ID NO: 20;

(b) a first dimerization domain (DD) module comprising two polypeptides, wherein:

(i) the first polypeptide of the first DD comprises one of C H 1 and C L ; and

(ii) the second polypeptide of the first DD comprises the other one of C H 1 and C L ;

and either:

(c1) a binding module (BM) comprising:

(i) the antigen-binding sites of:

(A) amino acid positions 1 to 119 of SEQ ID NO: 17 and amino acid positions 125 to 231 of SEQ ID NO: 18, or amino acid positions 1 to 119 of SEQ ID NO: 18 and amino acid positions 125 to 235 of SEQ ID NO: 17;

and

(ii) and a second DD module comprising two polypeptides, wherein:

(A) the first polypeptide of the second DD module comprises one of CH1 and CL, and the second polypeptide of the second DD module comprises the other one of CH1 and CL;

(B) the first polypeptide of the second DD comprises a CH2 domain of IgM (MHD2) and the second polypeptide of the second DD comprises a CH2 domain of IgM (MHD2);

(C) the first polypeptide of the second DD comprises CH2 domain of IgE (EHD2) and the second polypeptide of the second DD comprises CH2 domain of IgE (EHD2);

or

(D) the first polypeptide of the second DD comprises heterodimeric EHD2 (hetEHD2) and the second polypeptide of the second DD comprises hetEHD2;

or

(c2) a second dual binding module (DBM2) comprising:

(i) the same antigen-binding sites as DBM1; and

(ii) a second DD module comprising two polypeptides, wherein:

(A) the first polypeptide of the second DD comprises MHD2 and the second polypeptide of the second DD comprises MHD2;

(B) the first polypeptide of the second DD comprises EHD2 and the second polypeptide of the second DD comprises EHD2;

or

(C) the first polypeptide of the second DD comprises hetEHD2 and the second polypeptide of the second DD comprises hetEHD2.

2 . The multivalent antigen-binding protein complex according to claim 1 , wherein the antigen-binding protein complex further comprises a heterodimerization domain (HDM) directly or indirectly linked to the DD module, wherein the

HDM comprises two polypeptides, wherein each HDM polypeptide comprises:

(i) an Fc-part; or

(ii) a heterodimerizing Fc-part of an antibody.

3 . The multivalent antigen-binding protein complex according to claim 1 , wherein the antigen-binding sites of SEQ ID NO: 19 and SEQ ID NO: 20 are connected by a peptide linker (L1) having a length of between 4 and 12 amino acid.

4 . The multivalent antigen-binding protein complex according to claim 1 , wherein the antigen-binding protein complex further comprises a homodimerization or heterodimerization domain (HDM), wherein the HDM comprises two polypeptides, wherein the first HDM polypeptide is directly or indirectly linked to the first DD module, and the second HDM polypeptide is directly or indirectly linked to the second DD module, wherein each HDM polypeptide comprises:

(i) an Fc-part; or

(ii) a heterodimerizing Fc-part of an antibody.

5 . The multivalent antigen-binding protein complex according to claim 1 , wherein the antigen-binding sites of SEQ ID NO: 17, and SEQ ID NO: 18 are connected by a peptide linker (L1) having a length of between 4 and 12 amino acid, and wherein the antigen-binding sites of BM are connected by a peptide linker (L1) having a length of between 4 and 12 amino acid.

6 . The multivalent antigen-binding protein complex according to claim 1 , wherein the antigen-binding protein complex further comprises a homodimerization or heterodimerization domain (HDM), wherein the HDM comprises two polypeptides, wherein the first HDM polypeptide is directly or indirectly linked to the first DD module, and the second HDM polypeptide is directly or indirectly linked to the second DD module, wherein each HDM polypeptide comprises:

(i) an Fc-part; or

(ii) a heterodimerizing Fc-part of an antibody.

7 . The multivalent antigen-binding protein complex according to claim 1 , wherein the antigen-binding protein complex comprises:

(i) the amino acid sequence of SEQ ID NO: 17 and SEQ ID NO: 18;

(ii) the amino acid sequence of SEQ ID NO: 19 and SEQ ID NO: 20; or

(iii) the amino acid sequence of SEQ ID NO: 32 and SEQ ID NO: 33.

8 . The multivalent antigen-binding protein complex of claim 1 , further comprising at least one pharmaceutically active moiety and/or imaging molecule.

9 . The multivalent antigen-binding protein complex of claim 8 , wherein the pharmaceutically active moiety is selected from the group consisting of a ligand and an effector molecule.

10 . The multivalent antigen-binding protein complex of claim 9 , wherein the ligand is selected from the group consisting of an antigen-binding molecule, a scaffold protein, a ligand, a ligand-binding receptor fragment, and an aptamer.

11 . A method for treatment of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3) expressing cancer, the method comprising administering to a subject in need thereof an effective amount of the antigen-binding protein complex of claim 1 .

12 . The antigen-binding protein complex of claim 10 , wherein the antigen-binding molecule is selected from the group consisting of a Fab fragment, a Fab′ fragment, a heavy chain antibody, a single-domain antibody (sdAb), variable domain of a heavy chain antibody, a single-chain variable fragment (scFv), a tandem scFv, a single-chain diabody, a triple body, a nanoantibody, and a fusion protein thereof.

13 . The antigen-binding protein complex of claim 9 , wherein the effector molecule is an immune (co)-stimulatory molecule.

Assignments (1)

Continuity (2)

References Cited (20)